SG187965A1 - Notum protein modulators and methods of use - Google Patents

Info

Publication number

SG187965A1

SG187965A1 SG2013014261A SG2013014261A SG187965A1 SG 187965 A1 SG187965 A1 SG 187965A1 SG 2013014261 A SG2013014261 A SG 2013014261A SG 2013014261 A SG2013014261 A SG 2013014261A SG 187965 A1 SG187965 A1 SG 187965A1

Authority

SG

Singapore

Prior art keywords

notum

seq

modulator

cancer

antibody

Prior art date

2010-08-27

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 268
• 101150025249 Notum gene Proteins 0.000 title claims description 466
• 229940076155 protein modulator Drugs 0.000 title description 2
• 230000003463 hyperproliferative effect Effects 0.000 claims abstract description 18
• 210000004027 cell Anatomy 0.000 claims description 337
• 206010028980 Neoplasm Diseases 0.000 claims description 255
• 241000282414 Homo sapiens Species 0.000 claims description 117
• 210000005102 tumor initiating cell Anatomy 0.000 claims description 103
• 239000012634 fragment Substances 0.000 claims description 83
• 150000007523 nucleic acids Chemical class 0.000 claims description 77
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
• 102000039446 nucleic acids Human genes 0.000 claims description 68
• 108020004707 nucleic acids Proteins 0.000 claims description 68
• 208000035475 disorder Diseases 0.000 claims description 60
• 239000002246 antineoplastic agent Substances 0.000 claims description 56
• 239000000203 mixture Substances 0.000 claims description 55
• 210000001519 tissue Anatomy 0.000 claims description 54
• 238000011282 treatment Methods 0.000 claims description 50
• 210000004881 tumor cell Anatomy 0.000 claims description 49
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 45
• 230000009467 reduction Effects 0.000 claims description 45
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
• 238000000338 in vitro Methods 0.000 claims description 37
• 239000013598 vector Substances 0.000 claims description 37
• 238000001727 in vivo Methods 0.000 claims description 36
• 150000001413 amino acids Chemical class 0.000 claims description 33
• 241000699670 Mus sp. Species 0.000 claims description 30
• 230000001613 neoplastic effect Effects 0.000 claims description 28
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 27
• 238000007798 limiting dilution analysis Methods 0.000 claims description 27
• 230000035772 mutation Effects 0.000 claims description 27
• 238000004519 manufacturing process Methods 0.000 claims description 26
• 239000005557 antagonist Substances 0.000 claims description 25
• 229940127089 cytotoxic agent Drugs 0.000 claims description 24
• 206010009944 Colon cancer Diseases 0.000 claims description 21
• 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 21
• 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 20
• 206010027476 Metastases Diseases 0.000 claims description 18
• 239000002254 cytotoxic agent Substances 0.000 claims description 18
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 17
• 230000001404 mediated effect Effects 0.000 claims description 16
• 230000009401 metastasis Effects 0.000 claims description 16
• 230000000670 limiting effect Effects 0.000 claims description 13
• 230000000779 depleting effect Effects 0.000 claims description 12
• 102000037865 fusion proteins Human genes 0.000 claims description 12
• 108020001507 fusion proteins Proteins 0.000 claims description 12
• 230000002401 inhibitory effect Effects 0.000 claims description 12
• 230000001603 reducing effect Effects 0.000 claims description 12
• 230000003472 neutralizing effect Effects 0.000 claims description 11
• 230000002829 reductive effect Effects 0.000 claims description 11
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
• 238000009826 distribution Methods 0.000 claims description 10
• 238000000684 flow cytometry Methods 0.000 claims description 10
• 239000000463 material Substances 0.000 claims description 10
• 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims description 9
• 206010061598 Immunodeficiency Diseases 0.000 claims description 8
• 206010060862 Prostate cancer Diseases 0.000 claims description 8
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
• 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 8
• 238000011002 quantification Methods 0.000 claims description 8
• 206010006187 Breast cancer Diseases 0.000 claims description 7
• 208000026310 Breast neoplasm Diseases 0.000 claims description 7
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
• 201000002528 pancreatic cancer Diseases 0.000 claims description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
• 206010014733 Endometrial cancer Diseases 0.000 claims description 6
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
• 206010033128 Ovarian cancer Diseases 0.000 claims description 6
• 238000000151 deposition Methods 0.000 claims description 6
• 238000010790 dilution Methods 0.000 claims description 6
• 239000012895 dilution Substances 0.000 claims description 6
• 208000014018 liver neoplasm Diseases 0.000 claims description 6
• 206010005003 Bladder cancer Diseases 0.000 claims description 5
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
• 206010069755 K-ras gene mutation Diseases 0.000 claims description 5
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
• 206010038389 Renal cancer Diseases 0.000 claims description 5
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
• 208000024447 adrenal gland neoplasm Diseases 0.000 claims description 5
• 201000010881 cervical cancer Diseases 0.000 claims description 5
• 230000008021 deposition Effects 0.000 claims description 5
• 239000003937 drug carrier Substances 0.000 claims description 5
• 230000001747 exhibiting effect Effects 0.000 claims description 5
• 201000010982 kidney cancer Diseases 0.000 claims description 5
• 201000007270 liver cancer Diseases 0.000 claims description 5
• 208000020816 lung neoplasm Diseases 0.000 claims description 5
• 230000001235 sensitizing effect Effects 0.000 claims description 5
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
• 102100028914 Catenin beta-1 Human genes 0.000 claims description 4
• 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 claims description 4
• 230000018732 detection of tumor cell Effects 0.000 claims description 4
• 238000013115 immunohistochemical detection Methods 0.000 claims description 4
• 230000014306 paracrine signaling Effects 0.000 claims description 4
• 230000008093 supporting effect Effects 0.000 claims description 4
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 3
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 3
• 238000009115 maintenance therapy Methods 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims 4
• 201000005188 adrenal gland cancer Diseases 0.000 claims 4
• 201000005202 lung cancer Diseases 0.000 claims 4
• 230000027455 binding Effects 0.000 description 120
• 108090000623 proteins and genes Proteins 0.000 description 109
• 230000014509 gene expression Effects 0.000 description 107
• 102000004169 proteins and genes Human genes 0.000 description 78
• 108090000765 processed proteins & peptides Proteins 0.000 description 77
• 235000018102 proteins Nutrition 0.000 description 73
• 102000004196 processed proteins & peptides Human genes 0.000 description 67
• 201000011510 cancer Diseases 0.000 description 57
• 239000000427 antigen Substances 0.000 description 54
• 229920001184 polypeptide Polymers 0.000 description 54
• 108091007433 antigens Proteins 0.000 description 53
• 102000036639 antigens Human genes 0.000 description 53
• 239000003795 chemical substances by application Substances 0.000 description 42
• 230000000694 effects Effects 0.000 description 42
• 150000001875 compounds Chemical class 0.000 description 39
• 108060003951 Immunoglobulin Proteins 0.000 description 38
• 102000018358 immunoglobulin Human genes 0.000 description 38
• 235000001014 amino acid Nutrition 0.000 description 37
• 210000000130 stem cell Anatomy 0.000 description 35
• -1 antisense constructs Proteins 0.000 description 31
• 230000001225 therapeutic effect Effects 0.000 description 28
• 108020004414 DNA Proteins 0.000 description 27
• 101000604110 Homo sapiens Palmitoleoyl-protein carboxylesterase NOTUM Proteins 0.000 description 26
• 241001465754 Metazoa Species 0.000 description 26
• 238000003556 assay Methods 0.000 description 26
• 238000005516 engineering process Methods 0.000 description 25
• 230000006870 function Effects 0.000 description 25
• 102000053159 human Notum Human genes 0.000 description 25
• 102000010956 Glypican Human genes 0.000 description 24
• 108050001154 Glypican Proteins 0.000 description 24
• 102000013814 Wnt Human genes 0.000 description 24
• 108050003627 Wnt Proteins 0.000 description 24
• 239000003814 drug Substances 0.000 description 24
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 22
• 239000013604 expression vector Substances 0.000 description 21
• 231100001221 nontumorigenic Toxicity 0.000 description 21
• 239000000523 sample Substances 0.000 description 21
• 230000011664 signaling Effects 0.000 description 21
• 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 20
• 230000001965 increasing effect Effects 0.000 description 20
• 239000003550 marker Substances 0.000 description 20
• 238000006467 substitution reaction Methods 0.000 description 20
• 241000699666 Mus <mouse, genus> Species 0.000 description 19
• 230000004927 fusion Effects 0.000 description 19
• 230000003993 interaction Effects 0.000 description 19
• 230000009261 transgenic effect Effects 0.000 description 19
• 239000012636 effector Substances 0.000 description 18
• 230000037361 pathway Effects 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 239000000126 substance Substances 0.000 description 18
• 241001529936 Murinae Species 0.000 description 17
• 238000004458 analytical method Methods 0.000 description 17
• 230000013595 glycosylation Effects 0.000 description 17
• 238000006206 glycosylation reaction Methods 0.000 description 17
• 238000003752 polymerase chain reaction Methods 0.000 description 17
• 238000000746 purification Methods 0.000 description 17
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
• 230000037396 body weight Effects 0.000 description 16
• 230000004048 modification Effects 0.000 description 16
• 238000012986 modification Methods 0.000 description 16
• 102000040430 polynucleotide Human genes 0.000 description 16
• 108091033319 polynucleotide Proteins 0.000 description 16
• 239000002157 polynucleotide Substances 0.000 description 16
• 238000002648 combination therapy Methods 0.000 description 15
• 201000010099 disease Diseases 0.000 description 15
• 239000003446 ligand Substances 0.000 description 15
• 229940079593 drug Drugs 0.000 description 14
• 238000009396 hybridization Methods 0.000 description 14
• 210000004408 hybridoma Anatomy 0.000 description 14
• 239000013612 plasmid Substances 0.000 description 14
• 230000035755 proliferation Effects 0.000 description 14
• 238000012216 screening Methods 0.000 description 14
• 241000894007 species Species 0.000 description 14
• 230000004083 survival effect Effects 0.000 description 14
• 238000013518 transcription Methods 0.000 description 14
• 230000035897 transcription Effects 0.000 description 14
• 102000044880 Wnt3A Human genes 0.000 description 13
• 108700013515 Wnt3A Proteins 0.000 description 13
• 125000000539 amino acid group Chemical group 0.000 description 13
• 238000001514 detection method Methods 0.000 description 13
• 230000004069 differentiation Effects 0.000 description 13
• 230000007246 mechanism Effects 0.000 description 13
• 239000002773 nucleotide Substances 0.000 description 13
• 125000003729 nucleotide group Chemical group 0.000 description 13
• 241000196324 Embryophyta Species 0.000 description 12
• 241000282553 Macaca Species 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• 208000005623 Carcinogenesis Diseases 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 230000036952 cancer formation Effects 0.000 description 11
• 231100000504 carcinogenesis Toxicity 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 230000012010 growth Effects 0.000 description 11
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 11
• 238000002823 phage display Methods 0.000 description 11
• 238000002360 preparation method Methods 0.000 description 11
• 239000000758 substrate Substances 0.000 description 11
• 238000012360 testing method Methods 0.000 description 11
• 108091028043 Nucleic acid sequence Proteins 0.000 description 10
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
• 238000013459 approach Methods 0.000 description 10
• 229920001223 polyethylene glycol Polymers 0.000 description 10
• 239000000047 product Substances 0.000 description 10
• 210000002966 serum Anatomy 0.000 description 10
• 238000002560 therapeutic procedure Methods 0.000 description 10
• 108060000903 Beta-catenin Proteins 0.000 description 9
• 102100030708 GTPase KRas Human genes 0.000 description 9
• 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 9
• 210000003719 b-lymphocyte Anatomy 0.000 description 9
• 230000004663 cell proliferation Effects 0.000 description 9
• 239000003153 chemical reaction reagent Substances 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 230000003247 decreasing effect Effects 0.000 description 9
• 230000002255 enzymatic effect Effects 0.000 description 9
• 230000002068 genetic effect Effects 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 238000001959 radiotherapy Methods 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 230000004614 tumor growth Effects 0.000 description 9
• 231100000588 tumorigenic Toxicity 0.000 description 9
• 102000015735 Beta-catenin Human genes 0.000 description 8
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
• 108010087819 Fc receptors Proteins 0.000 description 8
• 102000009109 Fc receptors Human genes 0.000 description 8
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 8
• 108700026244 Open Reading Frames Proteins 0.000 description 8
• 238000007792 addition Methods 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 238000012512 characterization method Methods 0.000 description 8
• 230000000295 complement effect Effects 0.000 description 8
• 231100000433 cytotoxic Toxicity 0.000 description 8
• 230000001472 cytotoxic effect Effects 0.000 description 8
• 230000007423 decrease Effects 0.000 description 8
• 238000011161 development Methods 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000008030 elimination Effects 0.000 description 8
• 238000003379 elimination reaction Methods 0.000 description 8
• 230000003053 immunization Effects 0.000 description 8
• 239000000367 immunologic factor Substances 0.000 description 8
• 230000001939 inductive effect Effects 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 229960004768 irinotecan Drugs 0.000 description 8
• 239000002953 phosphate buffered saline Substances 0.000 description 8
• 239000000243 solution Substances 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 231100000765 toxin Toxicity 0.000 description 8
• 230000014616 translation Effects 0.000 description 8
• 230000000381 tumorigenic effect Effects 0.000 description 8
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 7
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 7
• 108091026890 Coding region Proteins 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 239000002202 Polyethylene glycol Substances 0.000 description 7
• 238000011529 RT qPCR Methods 0.000 description 7
• 108020004511 Recombinant DNA Proteins 0.000 description 7
• 241000700605 Viruses Species 0.000 description 7
• 229940112869 bone morphogenetic protein Drugs 0.000 description 7
• 230000021615 conjugation Effects 0.000 description 7
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
• 239000000446 fuel Substances 0.000 description 7
• 230000036210 malignancy Effects 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 230000000051 modifying effect Effects 0.000 description 7
• 210000005170 neoplastic cell Anatomy 0.000 description 7
• 230000009826 neoplastic cell growth Effects 0.000 description 7
• 230000008569 process Effects 0.000 description 7
• 238000012545 processing Methods 0.000 description 7
• 150000003384 small molecules Chemical class 0.000 description 7
• 239000003053 toxin Substances 0.000 description 7
• 108700012359 toxins Proteins 0.000 description 7
• 238000001890 transfection Methods 0.000 description 7
• 238000013519 translation Methods 0.000 description 7
• 239000003981 vehicle Substances 0.000 description 7
• 101100442150 Drosophila melanogaster dally gene Proteins 0.000 description 6
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 6
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 description 6
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
• 230000009471 action Effects 0.000 description 6
• 239000002671 adjuvant Substances 0.000 description 6
• 150000001720 carbohydrates Chemical class 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 230000024245 cell differentiation Effects 0.000 description 6
• 230000001413 cellular effect Effects 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 230000003325 follicular Effects 0.000 description 6
• 230000030279 gene silencing Effects 0.000 description 6
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 230000005764 inhibitory process Effects 0.000 description 6
• 238000002955 isolation Methods 0.000 description 6
• 239000003607 modifier Substances 0.000 description 6
• 238000012544 monitoring process Methods 0.000 description 6
• 201000000050 myeloid neoplasm Diseases 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 230000004044 response Effects 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 5
• 102100032912 CD44 antigen Human genes 0.000 description 5
• 108010092160 Dactinomycin Proteins 0.000 description 5
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 5
• 241000588724 Escherichia coli Species 0.000 description 5
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 5
• 241000282412 Homo Species 0.000 description 5
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 5
• 101000610551 Homo sapiens Prominin-1 Proteins 0.000 description 5
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 5
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 5
• 108060001084 Luciferase Proteins 0.000 description 5
• 239000005089 Luciferase Substances 0.000 description 5
• 206010025323 Lymphomas Diseases 0.000 description 5
• 102100039373 Membrane cofactor protein Human genes 0.000 description 5
• 108091034117 Oligonucleotide Proteins 0.000 description 5
• 102100040120 Prominin-1 Human genes 0.000 description 5
• 108010076504 Protein Sorting Signals Proteins 0.000 description 5
• 206010039491 Sarcoma Diseases 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 239000002253 acid Substances 0.000 description 5
• 230000003321 amplification Effects 0.000 description 5
• 230000003042 antagnostic effect Effects 0.000 description 5
• 230000000118 anti-neoplastic effect Effects 0.000 description 5
• 230000000692 anti-sense effect Effects 0.000 description 5
• 210000000628 antibody-producing cell Anatomy 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 239000000872 buffer Substances 0.000 description 5
• 210000004899 c-terminal region Anatomy 0.000 description 5
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 5
• 238000003776 cleavage reaction Methods 0.000 description 5
• 239000000824 cytostatic agent Substances 0.000 description 5
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
• 239000003623 enhancer Substances 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 238000003199 nucleic acid amplification method Methods 0.000 description 5
• 231100000590 oncogenic Toxicity 0.000 description 5
• 230000002246 oncogenic effect Effects 0.000 description 5
• 238000011275 oncology therapy Methods 0.000 description 5
• 239000000546 pharmaceutical excipient Substances 0.000 description 5
• 230000002062 proliferating effect Effects 0.000 description 5
• 230000001737 promoting effect Effects 0.000 description 5
• 238000011321 prophylaxis Methods 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 238000003259 recombinant expression Methods 0.000 description 5
• 230000007017 scission Effects 0.000 description 5
• 238000012163 sequencing technique Methods 0.000 description 5
• 230000019491 signal transduction Effects 0.000 description 5
• 230000009870 specific binding Effects 0.000 description 5
• 238000003786 synthesis reaction Methods 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 238000011285 therapeutic regimen Methods 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 244000060234 Gmelina philippensis Species 0.000 description 4
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
• 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 4
• 101000984015 Homo sapiens Cadherin-1 Proteins 0.000 description 4
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
• 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 4
• 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• 102000000588 Interleukin-2 Human genes 0.000 description 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
• 241000282560 Macaca mulatta Species 0.000 description 4
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 102000018697 Membrane Proteins Human genes 0.000 description 4
• 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
• 108700008625 Reporter Genes Proteins 0.000 description 4
• 102100038081 Signal transducer CD24 Human genes 0.000 description 4
• 108020004459 Small interfering RNA Proteins 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 230000003213 activating effect Effects 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000009824 affinity maturation Effects 0.000 description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 description 4
• 239000003242 anti bacterial agent Substances 0.000 description 4
• 229940088710 antibiotic agent Drugs 0.000 description 4
• 235000014633 carbohydrates Nutrition 0.000 description 4
• 230000000973 chemotherapeutic effect Effects 0.000 description 4
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
• 230000001268 conjugating effect Effects 0.000 description 4
• 230000001086 cytosolic effect Effects 0.000 description 4
• 238000002405 diagnostic procedure Methods 0.000 description 4
• 238000012377 drug delivery Methods 0.000 description 4
• 210000003527 eukaryotic cell Anatomy 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 4
• 208000014829 head and neck neoplasm Diseases 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 235000019626 lipase activity Nutrition 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 239000006166 lysate Substances 0.000 description 4
• 238000012423 maintenance Methods 0.000 description 4
• 238000007726 management method Methods 0.000 description 4
• 201000001441 melanoma Diseases 0.000 description 4
• 108020004999 messenger RNA Proteins 0.000 description 4
• 208000037819 metastatic cancer Diseases 0.000 description 4
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 4
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
• 230000005305 organ development Effects 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 238000010561 standard procedure Methods 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 238000001356 surgical procedure Methods 0.000 description 4
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• 241000701161 unidentified adenovirus Species 0.000 description 4
• 229960004528 vincristine Drugs 0.000 description 4
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 4
• 238000005406 washing Methods 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 230000003442 weekly effect Effects 0.000 description 4
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
• 229920000936 Agarose Polymers 0.000 description 3
• 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 241000701022 Cytomegalovirus Species 0.000 description 3
• 238000002965 ELISA Methods 0.000 description 3
• 108090000371 Esterases Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 108010024636 Glutathione Proteins 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
• 102000043131 MHC class II family Human genes 0.000 description 3
• 108091054438 MHC class II family Proteins 0.000 description 3
• 101100187355 Mus musculus Notum gene Proteins 0.000 description 3
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
• 108010004729 Phycoerythrin Proteins 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 102000016611 Proteoglycans Human genes 0.000 description 3
• 108010067787 Proteoglycans Proteins 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 3
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 230000000996 additive effect Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 230000000340 anti-metabolite Effects 0.000 description 3
• 229940100197 antimetabolite Drugs 0.000 description 3
• 239000002256 antimetabolite Substances 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 238000003491 array Methods 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 230000008512 biological response Effects 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 230000032823 cell division Effects 0.000 description 3
• 239000013592 cell lysate Substances 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 230000005757 colony formation Effects 0.000 description 3
• 238000010276 construction Methods 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• 238000011443 conventional therapy Methods 0.000 description 3
• 239000010949 copper Substances 0.000 description 3
• 238000004132 cross linking Methods 0.000 description 3
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
• 239000002619 cytotoxin Substances 0.000 description 3
• 229960000640 dactinomycin Drugs 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 229960000975 daunorubicin Drugs 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 230000003292 diminished effect Effects 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• 229960004679 doxorubicin Drugs 0.000 description 3
• 229940000406 drug candidate Drugs 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 238000011156 evaluation Methods 0.000 description 3
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
• 238000001502 gel electrophoresis Methods 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 229960003180 glutathione Drugs 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 238000003364 immunohistochemistry Methods 0.000 description 3
• 239000002955 immunomodulating agent Substances 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 230000002452 interceptive effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 210000001165 lymph node Anatomy 0.000 description 3
• 210000004698 lymphocyte Anatomy 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
• 229960000485 methotrexate Drugs 0.000 description 3
• 108091070501 miRNA Proteins 0.000 description 3
• 239000002679 microRNA Substances 0.000 description 3
• 229960001156 mitoxantrone Drugs 0.000 description 3
• 238000010369 molecular cloning Methods 0.000 description 3
• 101150087123 nat gene Proteins 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 230000002611 ovarian Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 239000000825 pharmaceutical preparation Substances 0.000 description 3
• 229920000642 polymer Polymers 0.000 description 3
• 229920001282 polysaccharide Polymers 0.000 description 3
• 239000005017 polysaccharide Substances 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 230000002265 prevention Effects 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 239000012857 radioactive material Substances 0.000 description 3
• 238000003753 real-time PCR Methods 0.000 description 3
• 238000010188 recombinant method Methods 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 238000013207 serial dilution Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007790 solid phase Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 239000003381 stabilizer Substances 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 210000001685 thyroid gland Anatomy 0.000 description 3
• 230000001131 transforming effect Effects 0.000 description 3
• 230000005740 tumor formation Effects 0.000 description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 229960003048 vinblastine Drugs 0.000 description 3
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• 238000012049 whole transcriptome sequencing Methods 0.000 description 3
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
• YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 2
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
• VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
• 108010066676 Abrin Proteins 0.000 description 2
• 101800002638 Alpha-amanitin Proteins 0.000 description 2
• 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
• 108010006654 Bleomycin Proteins 0.000 description 2
• 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 2
• 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 208000011691 Burkitt lymphomas Diseases 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• 102000053642 Catalytic RNA Human genes 0.000 description 2
• 108090000994 Catalytic RNA Proteins 0.000 description 2
• 108010001857 Cell Surface Receptors Proteins 0.000 description 2
• 102000000844 Cell Surface Receptors Human genes 0.000 description 2
• 108091035707 Consensus sequence Proteins 0.000 description 2
• 241000699802 Cricetulus griseus Species 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 101710112752 Cytotoxin Proteins 0.000 description 2
• 238000001712 DNA sequencing Methods 0.000 description 2
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000012286 ELISA Assay Methods 0.000 description 2
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
• 229930189413 Esperamicin Natural products 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• 108010045438 Frizzled receptors Proteins 0.000 description 2
• 102000005698 Frizzled receptors Human genes 0.000 description 2
• 102100028461 Frizzled-9 Human genes 0.000 description 2
• GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 2
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• 108050007237 Glypican-3 Proteins 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 101710154606 Hemagglutinin Proteins 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
• 101001061405 Homo sapiens Frizzled-9 Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 102000004157 Hydrolases Human genes 0.000 description 2
• 108090000604 Hydrolases Proteins 0.000 description 2
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• 206010061309 Neoplasm progression Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
• 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
• 108090000526 Papain Proteins 0.000 description 2
• 101710182846 Polyhedrin Proteins 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• 101710176177 Protein A56 Proteins 0.000 description 2
• 239000013614 RNA sample Substances 0.000 description 2
• 208000006265 Renal cell carcinoma Diseases 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 206010041067 Small cell lung cancer Diseases 0.000 description 2
• 108091081024 Start codon Proteins 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 108010016283 TCF Transcription Factors Proteins 0.000 description 2
• 102000000479 TCF Transcription Factors Human genes 0.000 description 2
• 241000723873 Tobacco mosaic virus Species 0.000 description 2
• 101710120037 Toxin CcdB Proteins 0.000 description 2
• 102000040945 Transcription factor Human genes 0.000 description 2
• 108091023040 Transcription factor Proteins 0.000 description 2
• 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 2
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
• VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
• 238000012452 Xenomouse strains Methods 0.000 description 2
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
• 230000021736 acetylation Effects 0.000 description 2
• 238000006640 acetylation reaction Methods 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 229930183665 actinomycin Natural products 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 230000002776 aggregation Effects 0.000 description 2
• 238000004220 aggregation Methods 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 230000008485 antagonism Effects 0.000 description 2
• VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
• 230000001093 anti-cancer Effects 0.000 description 2
• 239000002257 antimetastatic agent Substances 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000008228 bacteriostatic water for injection Substances 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 238000010256 biochemical assay Methods 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 229940088954 camptosar Drugs 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000013043 chemical agent Substances 0.000 description 2
• 238000007385 chemical modification Methods 0.000 description 2
• 229910052804 chromium Inorganic materials 0.000 description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
• 238000011281 clinical therapy Methods 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 230000001010 compromised effect Effects 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 238000011461 current therapy Methods 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 230000015961 delipidation Effects 0.000 description 2
• 238000001212 derivatisation Methods 0.000 description 2
• 239000000032 diagnostic agent Substances 0.000 description 2
• 229940039227 diagnostic agent Drugs 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000007876 drug discovery Methods 0.000 description 2
• VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 230000002708 enhancing effect Effects 0.000 description 2
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
• 229960001904 epirubicin Drugs 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• 235000008191 folinic acid Nutrition 0.000 description 2
• 239000011672 folinic acid Substances 0.000 description 2
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
• 201000003444 follicular lymphoma Diseases 0.000 description 2
• 238000005194 fractionation Methods 0.000 description 2
• 229910052733 gallium Inorganic materials 0.000 description 2
• CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 206010017758 gastric cancer Diseases 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 229940127121 immunoconjugate Drugs 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000016784 immunoglobulin production Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 229910052738 indium Inorganic materials 0.000 description 2
• APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229940079322 interferon Drugs 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 239000011630 iodine Substances 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 230000002147 killing effect Effects 0.000 description 2
• 229960001691 leucovorin Drugs 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 239000006193 liquid solution Substances 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 230000007774 longterm Effects 0.000 description 2
• 230000000527 lymphocytic effect Effects 0.000 description 2
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 2
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000002826 magnetic-activated cell sorting Methods 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 229910052748 manganese Inorganic materials 0.000 description 2
• 230000035800 maturation Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 235000013336 milk Nutrition 0.000 description 2
• 239000008267 milk Substances 0.000 description 2
• 210000004080 milk Anatomy 0.000 description 2
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
• 229960005485 mitobronitol Drugs 0.000 description 2
• 229960004857 mitomycin Drugs 0.000 description 2
• 229910052750 molybdenum Inorganic materials 0.000 description 2
• 239000011733 molybdenum Substances 0.000 description 2
• 108010093470 monomethyl auristatin E Proteins 0.000 description 2
• 108010059074 monomethylauristatin F Proteins 0.000 description 2
• 230000000877 morphologic effect Effects 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 229960000951 mycophenolic acid Drugs 0.000 description 2
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
• 108010068617 neonatal Fc receptor Proteins 0.000 description 2
• 230000001537 neural effect Effects 0.000 description 2
• 238000007481 next generation sequencing Methods 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 238000011369 optimal treatment Methods 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• 229940055729 papain Drugs 0.000 description 2
• 235000019834 papain Nutrition 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 210000001322 periplasm Anatomy 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 229940127557 pharmaceutical product Drugs 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
• 229960003171 plicamycin Drugs 0.000 description 2
• 230000004481 post-translational protein modification Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 229950010131 puromycin Drugs 0.000 description 2
• 230000003439 radiotherapeutic effect Effects 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 210000000664 rectum Anatomy 0.000 description 2
• 230000008929 regeneration Effects 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 230000008672 reprogramming Effects 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 230000000717 retained effect Effects 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 108091092562 ribozyme Proteins 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
• 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
• 229910052711 selenium Inorganic materials 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
• 230000004654 survival pathway Effects 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229910052713 technetium Inorganic materials 0.000 description 2
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 229960001278 teniposide Drugs 0.000 description 2
• 229910052716 thallium Inorganic materials 0.000 description 2
• BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
• 125000003396 thiol group Chemical group [H]S* 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 229910052718 tin Inorganic materials 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 229910052722 tritium Inorganic materials 0.000 description 2
• 230000005751 tumor progression Effects 0.000 description 2
• 238000000108 ultra-filtration Methods 0.000 description 2
• 241001515965 unidentified phage Species 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
• 229960002066 vinorelbine Drugs 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229910052724 xenon Inorganic materials 0.000 description 2
• FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
• NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
• ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
• CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
• AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
• JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
• BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
• WVHGJJRMKGDTEC-WCIJHFMNSA-N 2-[(1R,4S,8R,10S,13S,16S,27R,34S)-34-[(2S)-butan-2-yl]-8,22-dihydroxy-13-[(2R,3S)-3-hydroxybutan-2-yl]-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetamide Chemical compound CC[C@H](C)[C@@H]1NC(=O)CNC(=O)[C@@H]2Cc3c([nH]c4cc(O)ccc34)[S@](=O)C[C@H](NC(=O)CNC1=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N2 WVHGJJRMKGDTEC-WCIJHFMNSA-N 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
• QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
• SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
• FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
• YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
• 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
• CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 108700001666 APC Genes Proteins 0.000 description 1
• 102100021501 ATP-binding cassette sub-family B member 5 Human genes 0.000 description 1
• 108010022752 Acetylcholinesterase Proteins 0.000 description 1
• 102000012440 Acetylcholinesterase Human genes 0.000 description 1
• 208000001783 Adamantinoma Diseases 0.000 description 1
• 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
• 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
• 102100035990 Adenosine receptor A2a Human genes 0.000 description 1
• 108010000239 Aequorin Proteins 0.000 description 1
• 241000589158 Agrobacterium Species 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
• CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
• 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
• 108010027164 Amanitins Proteins 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
• 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
• 108091023037 Aptamer Proteins 0.000 description 1
• 241000219194 Arabidopsis Species 0.000 description 1
• 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 102100035682 Axin-1 Human genes 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 102100032481 B-cell CLL/lymphoma 9 protein Human genes 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• 102100024775 Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
• 101800001350 Beta-amanitin Proteins 0.000 description 1
• 102100026189 Beta-galactosidase Human genes 0.000 description 1
• 229940122361 Bisphosphonate Drugs 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 1
• 208000017234 Bone cyst Diseases 0.000 description 1
• 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
• 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
• 102100024210 CD166 antigen Human genes 0.000 description 1
• 102100038078 CD276 antigen Human genes 0.000 description 1
• 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
• 102100037904 CD9 antigen Human genes 0.000 description 1
• 102100025659 Cadherin EGF LAG seven-pass G-type receptor 1 Human genes 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 101710158575 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase Proteins 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 108090000007 Carboxypeptidase M Proteins 0.000 description 1
• 102100032936 Carboxypeptidase M Human genes 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 208000001843 Carotid Body Tumor Diseases 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 102100035888 Caveolin-1 Human genes 0.000 description 1
• 102100038909 Caveolin-2 Human genes 0.000 description 1
• 241000282552 Chlorocebus aethiops Species 0.000 description 1
• 102000009016 Cholera Toxin Human genes 0.000 description 1
• 108010049048 Cholera Toxin Proteins 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 108090000317 Chymotrypsin Proteins 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000186216 Corynebacterium Species 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 108700032819 Croton tiglium crotin II Proteins 0.000 description 1
• 229930188224 Cryptophycin Natural products 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 101150074155 DHFR gene Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000005778 DNA damage Effects 0.000 description 1
• 231100000277 DNA damage Toxicity 0.000 description 1
• 230000008265 DNA repair mechanism Effects 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
• 102000004237 Decorin Human genes 0.000 description 1
• 108090000738 Decorin Proteins 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
• 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
• 108010002156 Depsipeptides Proteins 0.000 description 1
• 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
• 206010064581 Desmoplastic small round cell tumour Diseases 0.000 description 1
• AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
• AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 102000016607 Diphtheria Toxin Human genes 0.000 description 1
• 108010053187 Diphtheria Toxin Proteins 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 108700039700 Drosophila Notum Proteins 0.000 description 1
• 101000951871 Drosophila melanogaster Division abnormally delayed protein Proteins 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 229930193152 Dynemicin Natural products 0.000 description 1
• 101150028000 EED gene Proteins 0.000 description 1
• 102000012804 EPCAM Human genes 0.000 description 1
• 101150084967 EPCAM gene Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 102100037241 Endoglin Human genes 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
• 238000011771 FVB mouse Methods 0.000 description 1
• 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
• 102100027286 Fanconi anemia group C protein Human genes 0.000 description 1
• 108091006020 Fc-tagged proteins Proteins 0.000 description 1
• 102100039036 Feline leukemia virus subgroup C receptor-related protein 1 Human genes 0.000 description 1
• 241000724791 Filamentous phage Species 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102100020997 Fractalkine Human genes 0.000 description 1
• 101710181403 Frizzled Proteins 0.000 description 1
• 102100021259 Frizzled-1 Human genes 0.000 description 1
• 102100021261 Frizzled-10 Human genes 0.000 description 1
• 102100021265 Frizzled-2 Human genes 0.000 description 1
• 102100039820 Frizzled-4 Human genes 0.000 description 1
• 102100039799 Frizzled-6 Human genes 0.000 description 1
• 102100039676 Frizzled-7 Human genes 0.000 description 1
• 102100028466 Frizzled-8 Human genes 0.000 description 1
• 102100032523 G-protein coupled receptor family C group 5 member B Human genes 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 102100021337 Gap junction alpha-1 protein Human genes 0.000 description 1
• 206010064571 Gene mutation Diseases 0.000 description 1
• 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
• 229930186217 Glycolipid Natural products 0.000 description 1
• 108010015899 Glycopeptides Proteins 0.000 description 1
• 102000002068 Glycopeptides Human genes 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 108010051696 Growth Hormone Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
• 108090000031 Hedgehog Proteins Proteins 0.000 description 1
• 102000003693 Hedgehog Proteins Human genes 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 108091006054 His-tagged proteins Proteins 0.000 description 1
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
• 101000677872 Homo sapiens ATP-binding cassette sub-family B member 5 Proteins 0.000 description 1
• 101000783751 Homo sapiens Adenosine receptor A2a Proteins 0.000 description 1
• 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
• 101000874566 Homo sapiens Axin-1 Proteins 0.000 description 1
• 101000798495 Homo sapiens B-cell CLL/lymphoma 9 protein Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
• 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
• 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
• 101000914155 Homo sapiens Cadherin EGF LAG seven-pass G-type receptor 1 Proteins 0.000 description 1
• 101000714537 Homo sapiens Cadherin-2 Proteins 0.000 description 1
• 101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 1
• 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 description 1
• 101000881679 Homo sapiens Endoglin Proteins 0.000 description 1
• 101000914680 Homo sapiens Fanconi anemia group C protein Proteins 0.000 description 1
• 101001029786 Homo sapiens Feline leukemia virus subgroup C receptor-related protein 1 Proteins 0.000 description 1
• 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 1
• 101000819438 Homo sapiens Frizzled-1 Proteins 0.000 description 1
• 101000819451 Homo sapiens Frizzled-10 Proteins 0.000 description 1
• 101000819477 Homo sapiens Frizzled-2 Proteins 0.000 description 1
• 101000819458 Homo sapiens Frizzled-3 Proteins 0.000 description 1
• 101000885581 Homo sapiens Frizzled-4 Proteins 0.000 description 1
• 101000885673 Homo sapiens Frizzled-6 Proteins 0.000 description 1
• 101000885797 Homo sapiens Frizzled-7 Proteins 0.000 description 1
• 101001061408 Homo sapiens Frizzled-8 Proteins 0.000 description 1
• 101001014684 Homo sapiens G-protein coupled receptor family C group 5 member B Proteins 0.000 description 1
• 101000894966 Homo sapiens Gap junction alpha-1 protein Proteins 0.000 description 1
• 101001066129 Homo sapiens Glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101001078133 Homo sapiens Integrin alpha-2 Proteins 0.000 description 1
• 101000994365 Homo sapiens Integrin alpha-6 Proteins 0.000 description 1
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
• 101001050321 Homo sapiens Junctional adhesion molecule C Proteins 0.000 description 1
• 101001091205 Homo sapiens KiSS-1 receptor Proteins 0.000 description 1
• 101001043596 Homo sapiens Low-density lipoprotein receptor-related protein 3 Proteins 0.000 description 1
• 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 description 1
• 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 1
• 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
• 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
• 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
• 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 description 1
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
• 101000601048 Homo sapiens Nidogen-2 Proteins 0.000 description 1
• 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 1
• 101000720966 Homo sapiens Opsin-3 Proteins 0.000 description 1
• 101000605434 Homo sapiens Phospholipid phosphatase 2 Proteins 0.000 description 1
• 101000801640 Homo sapiens Phospholipid-transporting ATPase ABCA3 Proteins 0.000 description 1
• 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
• 101000620365 Homo sapiens Protein TMEPAI Proteins 0.000 description 1
• 101000770799 Homo sapiens Protein Wnt-10b Proteins 0.000 description 1
• 101000804728 Homo sapiens Protein Wnt-2b Proteins 0.000 description 1
• 101000954762 Homo sapiens Proto-oncogene Wnt-3 Proteins 0.000 description 1
• 101001134937 Homo sapiens Protocadherin alpha-10 Proteins 0.000 description 1
• 101001134801 Homo sapiens Protocadherin beta-2 Proteins 0.000 description 1
• 101000735377 Homo sapiens Protocadherin-7 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000651309 Homo sapiens Retinoic acid receptor responder protein 1 Proteins 0.000 description 1
• 101000650822 Homo sapiens Semaphorin-4B Proteins 0.000 description 1
• 101000693269 Homo sapiens Sphingosine 1-phosphate receptor 3 Proteins 0.000 description 1
• 101000648549 Homo sapiens Sushi domain-containing protein 4 Proteins 0.000 description 1
• 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
• 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
• 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
• 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 1
• 101000798702 Homo sapiens Transmembrane protease serine 4 Proteins 0.000 description 1
• 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
• 101000762128 Homo sapiens Tumor suppressor candidate 3 Proteins 0.000 description 1
• 101001135565 Homo sapiens Tyrosine-protein phosphatase non-receptor type 3 Proteins 0.000 description 1
• 240000005979 Hordeum vulgare Species 0.000 description 1
• 235000007340 Hordeum vulgare Nutrition 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• 101710123134 Ice-binding protein Proteins 0.000 description 1
• 101710082837 Ice-structuring protein Proteins 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 108700002232 Immediate-Early Genes Proteins 0.000 description 1
• 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
• 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
• 102100024065 Inhibitor of growth protein 1 Human genes 0.000 description 1
• 108020005350 Initiator Codon Proteins 0.000 description 1
• 102100025305 Integrin alpha-2 Human genes 0.000 description 1
• 102100032816 Integrin alpha-6 Human genes 0.000 description 1
• 102100025304 Integrin beta-1 Human genes 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 102100023429 Junctional adhesion molecule C Human genes 0.000 description 1
• 102100034845 KiSS-1 receptor Human genes 0.000 description 1
• SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
• XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
• SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
• 101150017554 LGR5 gene Proteins 0.000 description 1
• 102100038235 Large neutral amino acids transporter small subunit 2 Human genes 0.000 description 1
• 244000207740 Lemna minor Species 0.000 description 1
• 235000006439 Lemna minor Nutrition 0.000 description 1
• 229920001491 Lentinan Polymers 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 206010024612 Lipoma Diseases 0.000 description 1
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
• 102100021917 Low-density lipoprotein receptor-related protein 3 Human genes 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 description 1
• 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025280 Lymphocytosis Diseases 0.000 description 1
• VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
• 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010068116 Metastatic uterine cancer Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 244000302512 Momordica charantia Species 0.000 description 1
• 235000009811 Momordica charantia Nutrition 0.000 description 1
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
• 102100023123 Mucin-16 Human genes 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 101100058550 Mus musculus Bmi1 gene Proteins 0.000 description 1
• 101100310657 Mus musculus Sox1 gene Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 1
• 101150111783 NTRK1 gene Proteins 0.000 description 1
• RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
• 229930193140 Neomycin Natural products 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 108010088225 Nestin Proteins 0.000 description 1
• 102000008730 Nestin Human genes 0.000 description 1
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 241000208125 Nicotiana Species 0.000 description 1
• 102100037371 Nidogen-2 Human genes 0.000 description 1
• KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
• 102100039306 Nucleotide pyrophosphatase Human genes 0.000 description 1
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 229930187135 Olivomycin Natural products 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 102000043276 Oncogene Human genes 0.000 description 1
• 102000004140 Oncostatin M Human genes 0.000 description 1
• 108090000630 Oncostatin M Proteins 0.000 description 1
• 102100025909 Opsin-3 Human genes 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 208000000035 Osteochondroma Diseases 0.000 description 1
• 101710160107 Outer membrane protein A Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
• VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
• 208000008900 Pancreatic Ductal Carcinoma Diseases 0.000 description 1
• 102000019280 Pancreatic lipases Human genes 0.000 description 1
• 108050006759 Pancreatic lipases Proteins 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 206010033963 Parathyroid tumour Diseases 0.000 description 1
• 108010069873 Patched Receptors Proteins 0.000 description 1
• 102000000017 Patched Receptors Human genes 0.000 description 1
• 241000237988 Patellidae Species 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 108010057150 Peplomycin Proteins 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 108091093037 Peptide nucleic acid Proteins 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 102100038120 Phospholipid phosphatase 2 Human genes 0.000 description 1
• 102100033623 Phospholipid-transporting ATPase ABCA3 Human genes 0.000 description 1
• 241000219506 Phytolacca Species 0.000 description 1
• 101100413173 Phytolacca americana PAP2 gene Proteins 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
• 229920000805 Polyaspartic acid Polymers 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 235000001855 Portulaca oleracea Nutrition 0.000 description 1
• 238000012356 Product development Methods 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 102100022429 Protein TMEPAI Human genes 0.000 description 1
• 102100029062 Protein Wnt-10b Human genes 0.000 description 1
• 102100035289 Protein Wnt-2b Human genes 0.000 description 1
• 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
• 101710109947 Protein kinase C alpha type Proteins 0.000 description 1
• 102100033412 Protocadherin alpha-10 Human genes 0.000 description 1
• 102100033437 Protocadherin beta-2 Human genes 0.000 description 1
• 102100034941 Protocadherin-7 Human genes 0.000 description 1
• 241000589516 Pseudomonas Species 0.000 description 1
• 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
• 108091008103 RNA aptamers Proteins 0.000 description 1
• 238000010240 RT-PCR analysis Methods 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 102100027682 Retinoic acid receptor responder protein 1 Human genes 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 208000008938 Rhabdoid tumor Diseases 0.000 description 1
• 206010073334 Rhabdoid tumour Diseases 0.000 description 1
• OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
• RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 108091006780 SLC19A2 Proteins 0.000 description 1
• 108060007753 SLC6A14 Proteins 0.000 description 1
• 102000005032 SLC6A14 Human genes 0.000 description 1
• 108091006238 SLC7A8 Proteins 0.000 description 1
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
• 241000235070 Saccharomyces Species 0.000 description 1
• 240000003946 Saponaria officinalis Species 0.000 description 1
• 108010084592 Saporins Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 241001274197 Scatophagus argus Species 0.000 description 1
• 101710107921 Secreted protein BARF1 Proteins 0.000 description 1
• 102100027717 Semaphorin-4B Human genes 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
• 229920000519 Sizofiran Polymers 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 102100038803 Somatotropin Human genes 0.000 description 1
• 102100025747 Sphingosine 1-phosphate receptor 3 Human genes 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 241000256251 Spodoptera frugiperda Species 0.000 description 1
• 241000187747 Streptomyces Species 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• 102100028860 Sushi domain-containing protein 4 Human genes 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
• 101150057140 TACSTD1 gene Proteins 0.000 description 1
• 108700026226 TATA Box Proteins 0.000 description 1
• 102000043168 TGF-beta family Human genes 0.000 description 1
• 108091085018 TGF-beta family Proteins 0.000 description 1
• CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 1
• 102100030104 Thiamine transporter 1 Human genes 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
• 201000009365 Thymic carcinoma Diseases 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
• 101710183280 Topoisomerase Proteins 0.000 description 1
• 102100023489 Transcription factor 4 Human genes 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 108010033576 Transferrin Receptors Proteins 0.000 description 1
• 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
• 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 102100032471 Transmembrane protease serine 4 Human genes 0.000 description 1
• 108010021119 Trichosanthin Proteins 0.000 description 1
• UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 244000098338 Triticum aestivum Species 0.000 description 1
• 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
• 102100024248 Tumor suppressor candidate 3 Human genes 0.000 description 1
• YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
• 101710107540 Type-2 ice-structuring protein Proteins 0.000 description 1
• 102100033131 Tyrosine-protein phosphatase non-receptor type 3 Human genes 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
• 240000001866 Vernicia fordii Species 0.000 description 1
• 101150019524 WNT2 gene Proteins 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 108010047118 Wnt Receptors Proteins 0.000 description 1
• 102000006757 Wnt Receptors Human genes 0.000 description 1
• 230000004156 Wnt signaling pathway Effects 0.000 description 1
• 108700020986 Wnt-2 Proteins 0.000 description 1
• 102000052556 Wnt-2 Human genes 0.000 description 1
• 102000052549 Wnt-3 Human genes 0.000 description 1
• 101100485099 Xenopus laevis wnt2b-b gene Proteins 0.000 description 1
• 229910052769 Ytterbium Inorganic materials 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
• 108010088665 Zinc Finger Protein Gli2 Proteins 0.000 description 1
• 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
• 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
• IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
• XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
• 108010023617 abarelix Proteins 0.000 description 1
• AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
• 229960002184 abarelix Drugs 0.000 description 1
• 238000002679 ablation Methods 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• RUDNHCHNENLLKM-UHFFFAOYSA-N ac1mj1v6 Chemical compound O=C1NC(CC(O)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CSC1=C2C2=CC=C(O)C=C2N1 RUDNHCHNENLLKM-UHFFFAOYSA-N 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 229940022698 acetylcholinesterase Drugs 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 239000000443 aerosol Substances 0.000 description 1
• 239000007801 affinity label Substances 0.000 description 1
• 230000001270 agonistic effect Effects 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 108700025316 aldesleukin Proteins 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 239000004007 alpha amanitin Substances 0.000 description 1
• CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
• CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 208000008524 alveolar soft part sarcoma Diseases 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 230000009435 amidation Effects 0.000 description 1
• 238000007112 amidation reaction Methods 0.000 description 1
• 229960002684 aminocaproic acid Drugs 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 239000003957 anion exchange resin Substances 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 239000003080 antimitotic agent Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 238000011948 assay development Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• 208000012080 benign lipomatous neoplasm Diseases 0.000 description 1
• 239000004080 beta amanitin Substances 0.000 description 1
• 108010087667 beta-1,4-mannosyl-glycoprotein beta-1,4-N-acetylglucosaminyltransferase Proteins 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 102000005936 beta-Galactosidase Human genes 0.000 description 1
• IEQCUEXVAPAFMQ-UHFFFAOYSA-N beta-amanitin Natural products O=C1NC(CC(O)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 IEQCUEXVAPAFMQ-UHFFFAOYSA-N 0.000 description 1
• 108010079292 betaglycan Proteins 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 208000026900 bile duct neoplasm Diseases 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000012575 bio-layer interferometry Methods 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• OIPMQULDKWSNGX-UHFFFAOYSA-N bis[[ethoxy(oxo)phosphaniumyl]oxy]alumanyloxy-ethoxy-oxophosphanium Chemical compound [Al+3].CCO[P+]([O-])=O.CCO[P+]([O-])=O.CCO[P+]([O-])=O OIPMQULDKWSNGX-UHFFFAOYSA-N 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 229910052797 bismuth Inorganic materials 0.000 description 1
• JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
• 150000004663 bisphosphonates Chemical class 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960000455 brentuximab vedotin Drugs 0.000 description 1
• 229960005520 bryostatin Drugs 0.000 description 1
• MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
• MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 108700002839 cactinomycin Proteins 0.000 description 1
• 229950009908 cactinomycin Drugs 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 238000004422 calculation algorithm Methods 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940022399 cancer vaccine Drugs 0.000 description 1
• 238000009566 cancer vaccine Methods 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 231100000315 carcinogenic Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 108010047060 carzinophilin Proteins 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000033026 cell fate determination Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 239000002458 cell surface marker Substances 0.000 description 1
• 230000033077 cellular process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 230000003034 chemosensitisation Effects 0.000 description 1
• 230000035572 chemosensitivity Effects 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 238000011098 chromatofocusing Methods 0.000 description 1
• 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 229960002376 chymotrypsin Drugs 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 229960002173 citrulline Drugs 0.000 description 1
• 235000013477 citrulline Nutrition 0.000 description 1
• 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
• 238000012411 cloning technique Methods 0.000 description 1
• 238000003501 co-culture Methods 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 238000004581 coalescence Methods 0.000 description 1
• 230000001332 colony forming effect Effects 0.000 description 1
• 230000002301 combined effect Effects 0.000 description 1
• LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
• 239000012612 commercial material Substances 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000009137 competitive binding Effects 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 230000006552 constitutive activation Effects 0.000 description 1
• 239000005289 controlled pore glass Substances 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 239000000599 controlled substance Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 230000009260 cross reactivity Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 231100000409 cytocidal Toxicity 0.000 description 1
• 230000000445 cytocidal effect Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• 229960005052 demecolcine Drugs 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 230000000994 depressogenic effect Effects 0.000 description 1
• 230000002074 deregulated effect Effects 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 229950003913 detorubicin Drugs 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 229930191339 dianthin Natural products 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 1
• 229930188854 dolastatin Natural products 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 229960005501 duocarmycin Drugs 0.000 description 1
• 229930184221 duocarmycin Natural products 0.000 description 1
• FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
• 229950006700 edatrexate Drugs 0.000 description 1
• VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
• 229960002759 eflornithine Drugs 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
• XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
• 229950000549 elliptinium acetate Drugs 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 210000001671 embryonic stem cell Anatomy 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000008393 encapsulating agent Substances 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
• 229950010213 eniluracil Drugs 0.000 description 1
• 231100000655 enterotoxin Toxicity 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 238000001976 enzyme digestion Methods 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• 150000003883 epothilone derivatives Chemical class 0.000 description 1
• 201000004101 esophageal cancer Diseases 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229960005237 etoglucid Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 208000020603 familial colorectal cancer Diseases 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 239000010685 fatty oil Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000009123 feedback regulation Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 201000010073 fibrogenesis imperfecta ossium Diseases 0.000 description 1
• 201000010103 fibrous dysplasia Diseases 0.000 description 1
• 108091006047 fluorescent proteins Proteins 0.000 description 1
• 102000034287 fluorescent proteins Human genes 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• IEQCUEXVAPAFMQ-SXZCQOKQSA-N g729ypp47l Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 IEQCUEXVAPAFMQ-SXZCQOKQSA-N 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940044658 gallium nitrate Drugs 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• WVHGJJRMKGDTEC-UHFFFAOYSA-N gamma-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(C)O)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 WVHGJJRMKGDTEC-UHFFFAOYSA-N 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 229940020967 gemzar Drugs 0.000 description 1
• 238000011223 gene expression profiling Methods 0.000 description 1
• 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 102000005396 glutamine synthetase Human genes 0.000 description 1
• 108020002326 glutamine synthetase Proteins 0.000 description 1
• 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
• 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• 239000000185 hemagglutinin Substances 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 108060003552 hemocyanin Proteins 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 230000002440 hepatic effect Effects 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 229920006158 high molecular weight polymer Polymers 0.000 description 1
• 238000013537 high throughput screening Methods 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 238000001794 hormone therapy Methods 0.000 description 1
• 102000047486 human GAPDH Human genes 0.000 description 1
• 102000054751 human RUNX1T1 Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 150000007857 hydrazones Chemical class 0.000 description 1
• 230000003301 hydrolyzing effect Effects 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 230000002267 hypothalamic effect Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000002055 immunohistochemical effect Effects 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 230000003116 impacting effect Effects 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940100601 interleukin-6 Drugs 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000006525 intracellular process Effects 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 229960005386 ipilimumab Drugs 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 201000008632 juvenile polyposis syndrome Diseases 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 238000012484 label-free interaction analysis Methods 0.000 description 1
• 229910052746 lanthanum Inorganic materials 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 201000010260 leiomyoma Diseases 0.000 description 1
• 229940115286 lentinan Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 108020001756 ligand binding domains Proteins 0.000 description 1
• 229940040461 lipase Drugs 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 201000005252 lipomatous cancer Diseases 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 210000005228 liver tissue Anatomy 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
• 229950008745 losoxantrone Drugs 0.000 description 1
• 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
• HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
• 201000005249 lung adenocarcinoma Diseases 0.000 description 1
• RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
• 229950002654 lurtotecan Drugs 0.000 description 1
• 208000017830 lymphoblastoma Diseases 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 230000002934 lysing effect Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
• 229950008612 mannomustine Drugs 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
• VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 238000012775 microarray technology Methods 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 244000005700 microbiome Species 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 108010022050 mistletoe lectin I Proteins 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 229960003539 mitoguazone Drugs 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• CPTIBDHUFVHUJK-NZYDNVMFSA-N mitopodozide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 108010010621 modeccin Proteins 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 239000002991 molded plastic Substances 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 208000004707 mucinous cystadenoma Diseases 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 230000036457 multidrug resistance Effects 0.000 description 1
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 1
• ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• 229930014626 natural product Natural products 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 229960004927 neomycin Drugs 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 208000023833 nerve sheath neoplasm Diseases 0.000 description 1
• 210000005055 nestin Anatomy 0.000 description 1
• 201000011519 neuroendocrine tumor Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
• 229950009266 nogalamycin Drugs 0.000 description 1
• 230000001254 nonsecretory effect Effects 0.000 description 1
• 230000009701 normal cell proliferation Effects 0.000 description 1
• 230000012223 nuclear import Effects 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 229960002450 ofatumumab Drugs 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
• 229960001243 orlistat Drugs 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000003002 pH adjusting agent Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
• 229940116369 pancreatic lipase Drugs 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 210000003134 paneth cell Anatomy 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 201000010279 papillary renal cell carcinoma Diseases 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 238000000059 patterning Methods 0.000 description 1
• 102000004251 pectinacetylesterase Human genes 0.000 description 1
• 108010072638 pectinacetylesterase Proteins 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
• 229950003180 peplomycin Drugs 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000000816 peptidomimetic Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 230000003094 perturbing effect Effects 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 108010076042 phenomycin Proteins 0.000 description 1
• 208000028591 pheochromocytoma Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000010399 physical interaction Effects 0.000 description 1
• 230000008288 physiological mechanism Effects 0.000 description 1
• 230000006461 physiological response Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• 229960001221 pirarubicin Drugs 0.000 description 1
• 210000005059 placental tissue Anatomy 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 108700028325 pokeweed antiviral Proteins 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920000447 polyanionic polymer Polymers 0.000 description 1
• 108010064470 polyaspartate Proteins 0.000 description 1
• 229920002857 polybutadiene Polymers 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
• 238000002600 positron emission tomography Methods 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 230000036515 potency Effects 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229940071643 prefilled syringe Drugs 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 229940087463 proleukin Drugs 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 235000019419 proteases Nutrition 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 238000003498 protein array Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000002818 protein evolution Methods 0.000 description 1
• 238000000164 protein isolation Methods 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 108010061338 ranpirnase Proteins 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
• 230000037425 regulation of transcription Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 230000000754 repressing effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000979 retarding effect Effects 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 229950004892 rodorubicin Drugs 0.000 description 1
• IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229930182947 sarcodictyin Natural products 0.000 description 1
• 229940043230 sarcosine Drugs 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000002955 secretory cell Anatomy 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 238000007841 sequencing by ligation Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000011125 single therapy Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 229950001403 sizofiran Drugs 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 238000000638 solvent extraction Methods 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 125000006850 spacer group Chemical group 0.000 description 1
• 201000011096 spinal cancer Diseases 0.000 description 1
• 208000014618 spinal cord cancer Diseases 0.000 description 1
• 229950006315 spirogermanium Drugs 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
• 208000017572 squamous cell neoplasm Diseases 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 239000008223 sterile water Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 238000013517 stratification Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 238000002626 targeted therapy Methods 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 238000012956 testing procedure Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 206010043554 thrombocytopenia Diseases 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 230000008467 tissue growth Effects 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 230000014723 transformation of host cell by virus Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000001296 transplacental effect Effects 0.000 description 1
• 230000032258 transport Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
• 229960004560 triaziquone Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229930013292 trichothecene Natural products 0.000 description 1
• 150000003327 trichothecene derivatives Chemical class 0.000 description 1
• 229950010147 troxacitabine Drugs 0.000 description 1
• RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 229960001322 trypsin Drugs 0.000 description 1
• HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
• 239000000439 tumor marker Substances 0.000 description 1
• 102000003390 tumor necrosis factor Human genes 0.000 description 1
• 208000025443 tumor of adipose tissue Diseases 0.000 description 1
• 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
• MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
• 229950009811 ubenimex Drugs 0.000 description 1
• 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
• HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
• ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1
• 229960000641 zorubicin Drugs 0.000 description 1
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
• 229960005502 α-amanitin Drugs 0.000 description 1
• OFILNAORONITPV-ZUROAWGWSA-N ε-amanitin Chemical compound O=C1N[C@@H](CC(O)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@H](C)O)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 OFILNAORONITPV-ZUROAWGWSA-N 0.000 description 1